Altimmune, Inc. (NASDAQ:ALT – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $14.33.
Several research analysts have issued reports on ALT shares. Citigroup reissued a “market outperform” rating on shares of Altimmune in a research report on Friday. Wall Street Zen cut shares of Altimmune from a “sell” rating to a “strong sell” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating on shares of Altimmune in a research note on Tuesday, July 28th. B. Riley Financial reiterated a “buy” rating on shares of Altimmune in a research note on Friday. Finally, Weiss Ratings lowered Altimmune from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday.
Check Out Our Latest Stock Report on Altimmune
Altimmune Stock Performance
Shares of ALT opened at $1.56 on Friday. The company has a current ratio of 26.78, a quick ratio of 26.78 and a debt-to-equity ratio of 0.07. The firm has a market cap of $303.45 million, a PE ratio of -2.17 and a beta of 0.16. The company’s 50 day simple moving average is $2.55 and its 200-day simple moving average is $3.13. Altimmune has a 12-month low of $1.50 and a 12-month high of $6.44.
Altimmune (NASDAQ:ALT – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). As a group, equities analysts predict that Altimmune will post -0.58 EPS for the current year.
Insider Buying and Selling
In related news, CEO Jerome Durso acquired 30,700 shares of Altimmune stock in a transaction on Friday, November 13th. The stock was purchased at an average cost of $1.62 per share, with a total value of $49,734.00. Following the purchase, the chief executive officer directly owned 93,200 shares in the company, valued at approximately $150,984. The trade was a 49.12% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders purchased 50,700 shares of company stock worth $82,334. 1.60% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. raised its stake in shares of Altimmune by 12.0% during the third quarter. Goldman Sachs Group Inc. now owns 2,479,456 shares of the company’s stock worth $7,091,000 after purchasing an additional 265,006 shares during the last quarter. Nantahala Capital Management LLC grew its position in Altimmune by 14.7% in the 3rd quarter. Nantahala Capital Management LLC now owns 1,720,000 shares of the company’s stock valued at $4,919,000 after buying an additional 220,000 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Altimmune by 268.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,045,926 shares of the company’s stock valued at $3,221,000 after buying an additional 762,223 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Altimmune in the 2nd quarter valued at $2,097,000. Finally, Bank of America Corp DE increased its stake in Altimmune by 48.6% in the 1st quarter. Bank of America Corp DE now owns 570,203 shares of the company’s stock valued at $1,756,000 after buying an additional 186,420 shares during the period. 78.05% of the stock is currently owned by hedge funds and other institutional investors.
Altimmune Company Profile
Altimmune, Inc. is a clinical-stage biopharmaceutical company developing peptide-based treatments for obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland. Its lead candidate, pemvidutide, is an investigational medicine that activates GLP-1 and glucagon receptors. Altimmune has studied the drug for obesity and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Altimmune’s work focuses on advancing treatments through clinical development; pemvidutide is not an approved medicine.
Further Reading
- Five stocks we like better than Altimmune
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Altimmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altimmune and related companies with MarketBeat.com's FREE daily email newsletter.
